CAP Member Kenechukwu Ojukwu, MD, FCAP, discusses an analysis of Medicare data that revealed immunohistochemistry (IHC) claims associated with melanoma diagnoses grew from 11% to 51% between 2000 and 2017.
For the full article click here: Immunohistochemistry May Improve Melanoma Diagnosis